You haven't searched anything yet.
ABOUT ENSEM THERAPEUTICS:
ENSEM Therapeutics (“ENSEM”) is a Boston-based biopharmaceutical company focused on high value and difficult-to-drug targets in oncology to address unmet medical needs. The name ENSEM symbolizes innovations via the integration of groundbreaking Kinetic Ensem ble® technologies for drug design. The Company’s mission is to discover, develop, and commercialize transformative oncology therapies for patients, while leading the advancement of AI-driven structural ensemble and computational drug design. To this end, ENSEM has recently entered into an agreement with BeiGene which acquired an exclusive global license to ENSEM’s Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor and ENSEM anticipates multiple additional best-in-class or first-in-class agents from its growing pipeline to enter I the clinic in 2025 and 2026. These new programs will provide a rich opportunity for a motivated individual to lead the company’s business development effort.
Position:
The successful candidate will be a highly motivated and results-driven individual with extensive Oncology clinical development experience in biotech and/or pharma. They will work closely with preclinical Research team as well as external clinical consultants, drive the strategic planning and execution of first-in-human clinical trials through registrational studies.
Responsibilities:
Qualifications:
ENSEM Therapeutics, Inc. is an Equal Opportunity employer and does not discriminate against an applicant or employee because of race, creed, color, religion, sex, national origin, ancestry, age, sexual orientation, physical or mental disability, or veteran status.
The duties listed in this job description are intended only as illustrations of the various types of work that may be performed. The omission of specific statements of duties does not exclude them from the position if the work is similar, related, or a logical assignment to the position.
Full Time
$189k-256k (estimate)
06/26/2024
07/14/2024